127792-80-7

Basic information

• Product Name: 5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE
• Synonyms: 5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE;5-BroMo-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
• CAS NO: 127792-80-7
• Molecular Formula: C₁₃H₁₃BrN₂
• Molecular Weight: 277.16
• Mol File: 127792-80-7.mol

Chemical Properties

• Melting Point: 190-192°
• Boiling Point: 449.5°Cat760mmHg
• Flash Point: 225.6°C
• Appearance: /
• Density: 1.485g/cm³
• Vapor Pressure: 2.85E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE(127792-80-7)
• EPA Substance Registry System: 5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE(127792-80-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 127792-80-7(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE is used as a starting material for the synthesis of complex molecules due to its reactive properties and structural features. Its potential applications in medicinal chemistry are attributed to the possibility of altering its biological activity through structural modifications.
Used in Pharmaceutical Research:
In Pharmaceutical Research, 5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE is used as a compound of interest for exploring its potential biological activity. The presence of the brominated indole and pyridine ring may contribute to its interaction with biological targets, warranting further investigation into its therapeutic potential.
Used in Drug Development:
5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE is utilized in drug development as a candidate molecule that could be optimized for specific therapeutic applications. Its unique structure may offer advantages in the design of new drugs targeting various diseases and conditions.
Note: The specific applications and industries for 5-BROMO-3-(1,2,3,6-TETRAHYDRO-4-PYRIDINYL)-1H-INDOLE are not explicitly mentioned in the provided materials. The uses listed above are inferred based on the compound's potential in medicinal chemistry and pharmaceutical research. Further research is necessary to fully understand its potential uses and implications.

InChI:InChI=1/C13H13BrN2/c14-10-1-2-13-11(7-10)12(8-16-13)9-3-5-15-6-4-9/h1-3,7-8,15-16H,4-6H2/p+1

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 
• 41661-47-6 piperidin-4-one 
• 1215-59-4 5-benzyloxy-1H-indole 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 149669-42-1 5-bromo-3-[piperidine-4-yl]-1H-indole 

Relevant articles and documents

Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1

A series of 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives was synthesized and their biological activity was evaluated. The chemical structures of the newly prepared compounds were confirmed by 1H NMR, 13C NMR and ESI-HRMS spectra data. All tested compounds proved to be potent 5-HT1A receptor and serotonin transporter protein (SERT) ligands. Among them, compounds 15, 18, 19 and 30 showed significant affinity for 5-HT1A and SERT. Computer docking simulations carried out for compounds 15, 31 and 32 to models of 5-HT1A receptor and SERT confirm the results of biological tests. Due to high affinity for the 5-HT1A receptor and moderate affinity for SERT, compounds 31, 32, 35, and 37 were evaluated for their affinity for D2L, 5-HT6, 5-HT 7 and 5-HT2A receptors. In vivo tests, in turn, resulted in determining the functional activity of compounds 15, 18, 19 and 30 to the 5-HT1A receptor. The results of these tests indicate that all of the ligands possess properties characteristic of 5-HT1A receptor agonists.

Synthesis and structure-activity relationships of novel histamine H 1 antagonists: Indolylpiperidinyl benzoic acid derivatives

A series of indolylpiperidinyl derivatives were prepared and evaluated for their activity as histamine H1 antagonists. Structure-activity relationship studies were directed toward improving in vivo activity and pharmacokinetic profile of our first lead (1). Substitution of fluorine in position 6 on the indolyl ring led to higher in vivo activity in the inhibition of histamine-induced cutaneous vascular permeability assay but lower selectivity toward 5HT2 receptor. Extensive optimization was carried out within this series and a number of histamine H1 antagonists showing potency and long duration of action in vivo and low brain penetration or cardiotoxic potential were identified. Within this novel series, indolylpiperidines 15, 20, 48, 51 and 52 exhibited a long half-life in rat and have been selected for further preclinical evaluation.

Bisindoles as tachykinin receptor antagonists

This invention provides a series of substituted bisindole propanamides which are useful as tachykinin receptor antagonists and as serotonin agonists. This invention also provides methods for the treatment of related disorders as well as pharmaceutical for

1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake

The pharmaceutical use of novel compounds of formula I: where Z is a structure of formula A-B is -C=CH- or -C(R5)-CH2-; X is S or NR4; R1is H, halo, formyl, C1-C4alkyl, C1-C4alkoxy, thienylmethyloxy, 4,5-dihydrothiazol-2-yl, cyano, nitro, carboxamido, trifluoromethyl or hydroxy; R2is H or halo; R3is H, C1-C4alkyl, (C1-C4alkylene)-aryl, or -CH2-Y-NR7R8; R4is H, C1-C4alkyl, C1-C5acyl, or phenylsulfonyl; R5is H or OH; R6is H or methyl; Y is -CH2- or -C(O)-; R7is pyridinyl; and R8is H or -C(O)-(C3-C6cycloalkyl); and pharmaceutically acceptable salts thereof.

5-HT1F agonists for the treatment of migraine

This invention provides novel 5-HT1F agonists which are useful for the treatment of migraine and associated disorders.